Thomas D. Parker

TL;DR: Findings are consistent with vascular risk influencing late-life brain health via cerebral small-vessel disease and lower brain volumes but not amyloidosis; vascular risk screening and modification may need to be considered from early adulthood.

TL;DR: Data suggest distinct differences in cortical NDI and ODI occur in AD and these metrics provide pathologically relevant information beyond that of cortical thinning.

TL;DR: The sub-study design and protocol involves a prospective two time-point data collection covering clinical, neuropsychological, β-amyloid positron emission tomography and magnetic resonance imaging, biomarker and genetic information, which will provide an evidence base for the rational design of disease-modifying trials.

TL;DR: Three different blood-based techniques are compared to detect cortical 18F-florbetapir amyloid PET positivity in dementia-free members of Insight 46, a substudy of the population-based British 1946 birth cohort, and mass spectrometry plasma measures performed significantly better than any other measure, with greater cost savings demonstrated at lower prevalence.

TL;DR: The hypothesis that retinal neurodegeneration, measured using conventional OCT, is a useful biomarker for AD or PCA is not supported.